Johnson & Johnson 10-K Summary: Fiscal Year Ended January 3, 1999
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended January 3, 1999. Johnson & Johnson is a global healthcare company employing approximately 93,100 people. The company operates under a decentralized management structure across three primary segments: Consumer (personal care, hygiene, OTC drugs), Pharmaceutical (prescription drugs), and Professional (medical devices, surgical instruments). Operations span over 175 countries with manufacturing facilities in 36 countries outside the U.S.
Key Financial Metrics
The filing incorporates detailed financial statements by reference to the Annual Report to Shareowners; specific revenue, profit, and cash flow totals are not explicitly listed in the provided text. However, the following metrics are disclosed:
- Research & Development Costs: $2,269 million for fiscal year 1998 (compared to $2,140 million in 1997 and $1,905 million in 1996). These costs are charged directly to income.
- Market Capitalization: Approximately $117.2 billion (aggregate market value of voting stock held by non-affiliates as of February 23, 1999).
- Shares Outstanding: 1,345,589,883 shares of Common Stock as of February 23, 1999.
- Manufacturing Footprint: 175 facilities occupying approximately 17.8 million square feet globally.
- Reserves for Receivables: Total reserves deducted from trade accounts receivable were $385 million at the end of 1998.
Material Changes and Operational Updates
- Acquisition: In November 1998, the company completed the acquisition of DePuy, Inc., an orthopaedic products company, expanding the Professional segment into reconstructive, spinal, trauma, and sports medicine.
- Research Investment: R&D spending increased by approximately 6% year-over-year, rising from $2,140 million in 1997 to $2,269 million in 1998.
- Seasonality: Sales do not reflect significant seasonality, though spending is typically heavier in the fourth quarter due to advertising and research grants.
Outlook, Risks, and Contingencies
Regulatory Environment: The company faces increasing regulatory stringency globally, particularly from the U.S. FDA regarding product safety, efficacy, and testing documentation. Managed care trends are also influencing drug pricing and utilization.
Legal and Environmental: The company is involved in various legal proceedings, including Superfund environmental remediation cases. Management believes these proceedings will not have a material adverse effect on financial position or results of operations.
Competition: Competition is strong across all product lines, with significant pressure from research and development activities by competitors leading to potential product obsolescence.
Forward-Looking Statements: The filing includes a "Safe Harbor" statement regarding forward-looking information, noting that actual results may differ due to risks and uncertainties.
Investor Verification Checklist
- Verify the full consolidated financial statements (Revenue, Net Income, Cash Flow) in the referenced 1998 Annual Report to Shareowners (pages 31-44), as specific totals are not in this text.
- Review the impact of the DePuy acquisition on the Professional segment's future growth and integration costs.
- Assess the implications of rising R&D costs ($2.269 billion) on future profitability and product pipeline success.
- Monitor regulatory developments regarding drug pricing and FDA clearance requirements for new products.
- Examine the "Pending Legal Proceedings" note (referenced in the Annual Report) for details on specific litigation risks.